http://dspace.nbuv.gov.ua:80/handle/123456789/133115 2026-04-20T12:49:45Z http://dspace.nbuv.gov.ua:80/handle/123456789/139257 Medullary breast carcinoma Malyuchik, S.S.; Kiyamova, R.G. More then half a million cases each year makes breast cancer the most common malignancy in female. Medullary breast carcinoma (MBC) is a type of invasive ductal breast carcinoma that usually has favorable prognosis and is characterized by the high graded structure, high mitotic rate and heavy lymphoid infiltration. The last feature makes MBC an attractive subject for detailed studies in respect to development of novel immunological approaches for cancer treatment. In this review we have summarized the data on MBC morphology, antigenic repertoire and molecular biology features. The aim of this review was to illuminate the unique biological features and to outline theoretical basis for further investigations of MBC.; Рак молочной железы является наиболее распространенным онкологическим заболеванием среди женщин. Медуллярная карцинома молочной железы (МКМЖ) представляет собой вид инвазивного рака протоков молочной железы, который часто имеет благоприятный прогноз, характеризуется высоким уровнем дифференцировки, высоким митотический индексом и выраженной лимфоидной инфильтрацией. Именно это свойство делает МКМЖ привлекательной мишенью для детального изучения при разработке новых иммунотерапевтических подходов к лечению рака. В данном обзоре мы суммировали данные о морфологии, антигенном спектре и особенностях молекулярной биологии МКМЖ. Основная цель обзора — освещение уникальных биологических особенностей и определение теоретической основы для дальнейших исследований МКМЖ. 2008-01-01T00:00:00Z http://dspace.nbuv.gov.ua:80/handle/123456789/139224 Innovative policy of european institutes in solving cancer problems. The General Assembly of OECI, Genoa, Italy, May 21–24 Chekhun, V.F. The General Assembly and Scientific week of OECI (Organization of European Cancer Institutes) took place in Genoa (Italy) on 21–24 of May. The membership of OECI comprises 58 European cancer institutions, including R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine as the only representative from Ukraine. In the frames of Scientific week several important events took place: meeting on translational oncogeno­mics, workshop on cancer biotherapy, symposium on nanotechnology application in oncology, seminar on accreditation. OECI General Assembly closed the Scientific week. 2008-01-01T00:00:00Z http://dspace.nbuv.gov.ua:80/handle/123456789/139223 5-th International conference on cancer prevention summary. St. Gallen, Switzerland, March 6–8, 2008 Gallen, St. More than 180 international experts from 30 countries, including 10 participants from Kiev, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, met in St. Gallen, Switzerland for a three day conference to discuss the important issues of cancer prevention. The significance of problems highlighted during the Conference is doubtless, since “the worst forecast tells us that in 2030 world-wide there could be 27 million new cases of tumours and as many as 17 million deaths due to cancer” (Dr. F Cava­l­­li). The conference was opened by Prof. H.-J. Senn (MD, Conference-Co-Chairman and Local Organizer), who stressed that this Conference provides an “accumulated knowledge and growing interactions between molecular genetics and biology, epidemiology and clinical cancer prevention”, and “offers a comprehensive scientific discussion forum for the development of more rational cancer prevention for the future”. 2008-01-01T00:00:00Z http://dspace.nbuv.gov.ua:80/handle/123456789/139222 Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study Shestakova, T.; Zhuravel, E.; Bolgova, L.; Alekseenko, O.; Soldatkina, M.; Pogrebnoy, P. To analyze the patterns of human beta-defensin-1, 2, 4 (hBDs) expression in human lung tumors. Materials and Methods: Tissue samples of surgically resected human lung tumors (squamous cell carcinoma (SCC), n = 10; adenocarcinoma (AC), n = 10) paired with conditionally normal tissue samples were analized for expression of hBD-1, 2, 4 mRNA by semiquantitive RT-PCR. Results: In a number of studied lung cancer tissue samples, overexpression of defensin mRNA was registered: hBD-1 mRNA (50% of SCC and 60% AC), hBD-2 mRNA (60% of SCC and 50% of AC) or hBD-4 (40% of SCC and 20% AC). No correlation was detected between the levels of hBD-1, hBD-2 and hBD-4 mRNA and histological type, differentiation grade of the tumor, and the stage of the disease, as well as the content of hBD-2 peptide in blood serum of lung cancer patients. Conclusion: Human beta-defensins-1 and -2 are often up-regulated in human lung tumors.; Цель: проанализировать особенности экспрессии мРНК бета-дефенсинов-1, 2, 4 (hBDs) в ткани опухоли легкого человека. Материалы и методы: с помощью метода полуколичественного RT-PCR-анализа изучали уровень экспрессии мРНК hBD-1, 2, 4 в образцах ткани хирургически удаленных опухолей легкого человека (плоскоклеточный рак — ПКР, n = 10; аденокарцинома — AК, n = 10) по сравнению с образцами условно-нормальной ткани легкого тех же пациентов. Результаты: в ряде исследованных образцов опухолей легкого выявлена повышенная экспрессия мРНК hBD-1 (50% ПКР и 60% AК), hBD-2 (60% ПКР и 50% АК) или hBD-4 (40% ПКР и 20% AК). Зависимости между уровнем экспрессии бета-дефенсинов и гистологическим типом опухоли, стадией заболевания и содержанием пептида hBD-2 в сыворотке крови больных не установлено. Выводы: в ткани опухоли легкого человека часто активирована экспрессия hBD-1 и hBD-2. 2008-01-01T00:00:00Z